Polat, BulentOkur, Damla TugceColak, ArmaganYilmaz, KaderOzkaraca, MustafaComakli, Selim2024-10-262024-10-2620230268-89211435-604Xhttps://doi.org/10.1007/s10103-023-03847-6https://hdl.handle.net/20.500.12418/30016The main objective of this in vivo study was to investigate the effect of different low-level laser therapy (LLLT) doses on polycystic ovary syndrome (PCOS). In the present experimental study, a single dosage of estradiol valerate (EV) was administered to induce PCOS in female rats. After administration of the EV for induction of PCOS, rats were divided into 5 groups (n = 8/group): C group (animals that were not exposed to any form of procedure), PC group (no treatment following EV induction), L-1 group (1 J/cm(2) LLLT treatment following EV induction), L-2 group (2 J/cm(2) LLLT treatment following EV induction), L-3 group (6 J/cm(2) LLLT treatment following EV induction). The results indicated that no significant difference was found in the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and progesterone (P4) between the C and L-2 groups (p < 0.05). Although the serum levels of testosterone (T) were significantly higher in the C group compared with other groups (p < 0.05), the L-2 group was determined to be the closest to the C group. Additionally, the LH, FSH, and T receptor level of the L-2 group was closest to the C group. In conclusion, a 2 J/cm(2) dosage of LLLT (L-2 group) can be considered the most potentially effective treatment of PCOS in the rat. However, more studies are needed to determine the optimal dose of LLLT for the treatment of PCOS.en10.1007/s10103-023-03847-6info:eu-repo/semantics/closedAccessLow-level laser therapyPolycystic ovary syndromeRatEstradiol valerateArticle381375449392-s2.0-85166753203Q2WOS:001043150700001Q2